Form 4: Moderna President Stephen Hoge Reports Stock Transactions

Moderna's President, Stephen Hoge, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Stephen Hoge, President of Moderna, reported transactions involving Moderna common stock.
• On February 28, 2024, restricted stock units (RSUs) converted into 2,411 and 2,442 shares of common stock.
• Hoge sold 2,388 shares on February 29, 2024, at a price of $94.572 per share to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Hoge directly owns 1,515,898 shares and 1,518,286 shares of Moderna common stock.
• He also indirectly owns 4,116 shares through Valhalla, LLC and 151,933 shares through a trust.
• The sales were mandated by Moderna's equity incentive plans to cover tax obligations.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning executive interests with long-term shareholder value.
• Selling shares to cover tax obligations upon vesting of RSUs is a common practice among executives at publicly traded companies.
• Similar transactions are routinely reported by executives at comparable biotechnology companies like Pfizer, BioNTech, and Novavax.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares in the open market.
• The transactions are part of the executive's compensation package and are not expected to have a significant impact on the company's operations or financial condition.

Key Dates